Regulation of urokinase receptor function and pericellular proteolysis by the integrin α5β1

Thrombosis and Haemostasis

Volumn 101, Issue 5, 2009, Pages 954-962

  Bass, Rosemary ^a   Ellis, Vincent ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cell adhesion; Integrins; Plasminogen activation; uPA; uPAR

Indexed keywords

CD82 ANTIGEN; MANGANESE; MONOCLONAL ANTIBODY; PLASMINOGEN; TETRASPANIN; UROKINASE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELL TYPE; CHO CELL; COMPLEX FORMATION; DOWN REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN INTERACTION; REGULATORY MECHANISM;

ANIMALS; CELL ADHESION; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME ACTIVATION; FIBRONECTINS; HUMANS; KANGAI-1 PROTEIN; KINETICS; MANGANESE; PLASMINOGEN; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECEPTORS, VITRONECTIN; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 66149167316     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-08-0558     Document Type: Article

References (43)

1. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-2188. (Pubitemid 19057691)
2. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758. (Pubitemid 21907159)
3. Zhou HM, Nichols A, Meda P, et al. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000; 19: 4817-4826.
4. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-17984. (Pubitemid 37411359)
5. Ellis V, Murphy G. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett 2001; 506: 1-5. (Pubitemid 32925221)
6. Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol 2003; 54: 263-312. (Pubitemid 137639472)
7. Bass R, Ellis V. Cellular mechanisms regulating non-haemostatic plasmin generation. Biochem Soc Trans 2002; 30: 189-194.
8. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555. (Pubitemid 26301666)
9. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-10234. (Pubitemid 30202079)
10. Wei Y, Eble JA, Wang Z, et al. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol Biol Cell 2001; 12: 2975-2986. (Pubitemid 33062955)
11. Monaghan E, Gueorguiev V, Wilkins-Port C, et al. The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts. J Biol Chem 2004; 279: 1400-1407. (Pubitemid 38082667)
12. Wei Y, Czekay RP, Robillard L, et al. Regulation of α5β1 integrin conformation and function by urokinase receptor binding. J Cell Biol 2005; 168: 501-511. (Pubitemid 40205071)
13. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
14. Okumura Y, Kamikubo Y, Curriden SA, et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 2002; 277: 9395-9404.
15. Sidenius N, Andolfo A, Fesce R, et al. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 2002; 277: 27982-27990.
16. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104. (Pubitemid 30211799)
17. Aguirre-Ghiso JA, Liu D, Mignatti A, et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001; 12: 863-879. (Pubitemid 33051984)
18. Tarui T, Andronicos N, Czekay RP, et al. Critical role of integrin α5β1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem 2003; 278: 29863-29872. (Pubitemid 36962374)
19. Wei Y, Tang CH, Kim Y, et al. Urokinase receptors are required for α5β1 integrin-mediated signaling in tumor cells. J Biol Chem 2007; 282: 3929-3939. (Pubitemid 47084483)
20. Bass R, Werner F, Odintsova E, et al. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 2005; 280: 14811-14818. (Pubitemid 40562830)
21. Sechler JL, Corbett SA, Schwarzbauer JE. Modulatory roles for integrin activation and the synergy site of fibronectin during matrix assembly. Mol Biol Cell 1997; 8: 2563-2573. (Pubitemid 27528222)
22. Schreiner CL, Bauer JS, Danilov YN, et al. Isolation and characterization of Chinese hamster ovary cell variants deficient in the expression of fibronectin receptor. J Cell Biol 1989; 109: 3157-3167. (Pubitemid 20011939)
23. Coe AP, Askari JA, Kline AD, et al. Generation of a minimal α5β1 integrin-Fc fragment. J Biol Chem 2001; 276: 35854-35866.
24. Rønne E, Behrendt N, Ellis V, et al. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2- terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-236.
25. Messent AJ, Tuckwell DS, Knauper V, et al. Effects of collagenase-cleavage of type I collagen on α2β1 integrin-mediated cell adhesion. J Cell Sci 1998; 111: 1127-1135. (Pubitemid 28227112)
26. Liou AK, Willison KR. Elucidation of the subunit orientation in CCT (chaperonin containing TCP1) from the subunit composition of CCT micro-complexes. EMBO J 1997; 16: 4311-4316. (Pubitemid 27298184)
27. Bazzoni G, Ma L, Blue ML, et al. Divalent cations and ligands induce conformational changes that are highly divergent among β1 integrins. J Biol Chem 1998; 273: 6670-6678. (Pubitemid 28160325)
28. Mould AP, Garratt AN, Puzon-McLaughlin W, et al. Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin α5β1. Biochem J 1998; 331: 821-828. (Pubitemid 28211905)
29. Tarui T, Mazar AP, Cines DB, et al. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983-3990. (Pubitemid 37371480)
30. Elsasser S, Schmidt M, Finley D. Characterization of the proteasome using native gel electrophoresis. Methods Enzymol 2005; 398: 353-363. (Pubitemid 41578897)
31. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin αMβ2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 2003; 101: 1582-1590. (Pubitemid 36182538)
32. Pluskota E, Soloviev DA, Bdeir K, et al. Integrin αMβ2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 18063-18072. (Pubitemid 38560576)
33. Tarui T, Akakura N, Majumdar M, et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin αvβ3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95: 524-534.
34. Harris TJ, Siu CH. Reciprocal raft-receptor interactions and the assembly of adhesion complexes. Bioessays 2002; 24: 996-1003. (Pubitemid 35326157)
35. Yebra M, Goretzki L, Pfeifer M, et al. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 1999; 250: 231-240. (Pubitemid 29391587)
36. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001; 114: 4143-4151. (Pubitemid 33138652)
37. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003; 19: 397-422. (Pubitemid 37487354)
38. Yuan C, Huang M. Does the urokinase receptor exist in a latent form? Cell Mol Life Sci 2007; 64: 1033-1037.
39. Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-1663.
40. Huang M, Mazar AP, Parry G, et al. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). Acta Crystallogr D Biol Crystallogr 2005; 61: 697-700.
41. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase- type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom α-neurotoxins. FEBS Lett 1994; 349: 163-168.
42. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991-8997.
43. List K, Høyer-Hansen G, Rønne E, et al. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 1999; 222: 125-133. (Pubitemid 29023709)